23rd Annual Pain Medicine Meeting 2024

Unreliable Use of a Continuous Glucose Monitor in the Outpatient Procedural Setting

Evan Reuter, MD Ochsner Pain Medicine Fellow

Whitney Braddy, MD Ochsner Pain Medicine Fellowship Associate Program Director

Glucocorticoid injections pose risks to diabetic patients due to potential blood glucose elevation.
As CGMs become widespread, it may be tempting to defer facility testing and rely on patients' home monitors.
Reliable inpatient use of CGMs has been reported.
Used in COVID units
CGMs used inpatient required frequent calibration by nursing
FDA Guidelines
Known variance between capillary glucose and serum glucose
Permits CGM vs serum laboratory measures a difference of 20%.
Facility glucometers are calibrated every morning.
Home CGMs are intended to be calibrated every 10 days.

Patient presented for scheduled procedure
Patient has point of care glucose check due to diabetic status using facility POC capillary glucose test
Facility glucometer presents reading of 244 mg/dL
We informed patient of need to postpone procedure
Patient presents home CGM reading of 142 mg/dL. See figure 1.
Repeat facility glucometer readings are congruent with hyperglycemia.
Procedure is postponed.

We present an episode of an unreliable home CGM (continuous glucose monitor) at the time of an outpatient procedure. We share this case for all proceduralists to be aware that home CGMs cannot be trusted in procedure safety decisions.

23rd Annual Pain Medicine Meeting 2024

UNRELIABLE USE OF A CONTINUOUS GLUCOSE MONITOR IN THE OUTPATIENT PROCEDURAL SETTING

Poster Presenter

Authors

Affiliations

Part of Topic